Can you take rituximab while breastfeeding?

What LactMed would consider instead

LactMed ends this record by naming the drugs it would consider in place of rituximab. Whether any of them fits depends on what you are treating — this is the database’s list, not a recommendation from us.

• Glatiramer
• Immune Globulin
• Interferon Beta
• Adalimumab
• Certolizumab Pegol
• Etanercept
• Infliximab
• Tocilizumab

How much rituximab gets into breastmilk

Maternal Levels. A patient who had granulomatosis with polyangiitis received rituximab 1000 mg intravenously while exclusively breastfeeding her infant. Milk samples were collected daily for 4 days starting 7 days after the infusion. Milk rituximab concentrations averaged 0.5 mcg/L (range 0.4 to 0.6 mcg/L).

A woman with ANCA-associated vasculitis was treated with rituximab 500 mg intravenously at week 19 postpartum. The median concentration of rituximab in milk samples collected on 4 consecutive days was 3 mcg/L (range 0 to 4 mcg/L). The relative infant dose to the infant was estimated to be 0.007%.

An international, multicenter study of patients with multiple sclerosis or neuromyelitis optica spectrum disorder collected breastmilk samples from 26 women who were receiving rituximab. Milk samples were collected at a mean of 2.6 months (range 0.1–36.0) postpartum. The women received 500 mg once (n = 2) or twice (n = 9) or 1000 mg once (n = 11) or twice (n = 4) and milk samples were collected before and up to 90 days after the dose. Where measurable, the peak concentration in milk usually occurred between 1 and 7 days after the dose. Milk concentrations were virtually undetectable at 90 days after a dose. For women who received a single 500 mg dose, the average milk concentration was 0.03 mg/L, and the peak was 0.04 mg/L. For 10 women who receive a single 1000 mg dose, the average milk concentration was 0.04 mg/L, and the peak was 0.07 mg/L. For women who received two 500 mg doses, the average milk concentration was 0.02 mg/L, and the peak was 0.1 mg/L. For women who received two 1000 mg doses, the average milk concentration was 0.2 mg/L and the peak was 0.6 mg/L. Based on the average milk levels, infants would receive a dose between 0.003 and 0.03 mg/kg daily.

Six mothers with relapsing-remitting multiple sclerosis received 500 or 1,000 mg of rituximab postpartum. Breastmilk was collected at six time points: pre infusion, two days after infusion, after one week, and after one, three and five half-lives of rituximab. The highest concentration reported was in one woman who had a milk concentration of 250 mcg/L. The median average concentration in the breastmilk of the 6 women was 41 mcg/L.

Infant Levels. A woman received rituximab 375 mg/square meter once weekly for 4 weeks beginning at week 30 of gestation. Her infant was born at 40 weeks of gestation and was exclusively breastfed with no major health issues. At 4 months of age, trace amounts of rituximab heavy and light chains were detected, but not quantified, in the infant's serum. Whether the drug was acquired transplacentally or during breastfeeding was not determined.

A woman with ANCA-associated vasculitis was treated with rituximab 500 mg intravenously at week 19 postpartum. She continued to breastfeed her infant (extent not stated). There was no detectable rituximab in the serum of the infant (assay limit not stated) at 4 and 24 hours after the maternal dose.

Six nursing (extent not stated) mothers with relapsing-remitting multiple sclerosis received 500 or 1,000 mg of rituximab postpartum. Infant serum was collected at six time points: pre infusion, two days after infusion, after one week, and after one, three and five half-lives of rituximab. All of the measurements of rituximab concentration in the infants’ serum were below 0.01 mcg/L, and most of them below the lower limit of quantification (<0.005 mcg/L).

What has been seen in breastfed infants

A woman received rituximab 375 mg/square meter once weekly for 4 weeks beginning at week 30 of gestation. Her infant was born at 40 weeks of gestation and was exclusively breastfed with no major health issues. At 4 months of age, the infant's B-cell population and immunoglobulin levels did not appear to be affected.

A woman received an IV infusion of 1000 mg of rituximab at about 3 months postpartum. Her infant who was fully breastfed had no serious infections during the lactation period and developed normally during a 1.5 year follow-up period.

A retrospective cohort study from the German Multiple Sclerosis and Pregnancy Registry database identified 5 mothers who received rituximab during breastfeeding. Three mothers receive one dose of rituximab while nursing, one received 500 mg and two received 1000 mg. The infants breastfed for 1.6, 1.8 and 0.3 months, respectively. Infant blood counts were normal at 1 to 1.5 months after the mothers’ doses. A blood count was not performed in the third infant. One infant developed omphalitis, but all had normal development. The fourth woman received rituximab 250 mg on day 55 postpartum and ocrelizumab 300 mg on day 333 postpartum. She breastfed for 22.9 months after the rituximab dose. Her infant had normal blood counts at 45 and 213 days after the rituximab dose, but had conjunctivitis and otitis media during this time.

A woman was diagnosed with B-cell lymphoma at 27 weeks of pregnancy. Labor was induced at 34 4/7 weeks and treatment was begun with a standard regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in unspecified doses on a 21-day cycle, starting on day 2 postpartum. She pumped and discarded her milk and fed her infant donor milk for the first 10 days of each cycle and then breastfed her infant for the remaining 10 days before the next treatment cycle. The 10-day period of breastfeeding abstinence was determined by using about 3 half-lives of vincristine. After completion of 4 cycles of chemotherapy, her infant was reportedly healthy and developing without any complications.

A woman with ANCA-associated vasculitis was treated with rituximab 500 mg intravenously at week 19 postpartum. She continued to breastfeed her infant (extent not stated) for another 4 months. The infant did not experience any serious infections or allergies, developed normally during the following 2 years and received all recommended vaccinations.

Six nursing (extent not stated) mothers with relapsing-remitting multiple sclerosis received 500 or 1000 mg of rituximab postpartum. Infants were followed for at least 5 half-lives of the drug. No apparent abnormalities in the CD19 +B cell count, white blood cell count, lymphocytes or immunoglobulin levels were detected in the infants after rituximab infusion.

A multicenter study of women who were receiving either ocrelizumab (n = 30) or rituximab (n = 15) for multiple sclerosis or neuromyelitis optica spectrum disorder followed their infants. Forty-three women breastfed their infants (n = 27 exclusively, n = 16 partially) for a median of 6.4 months (range 0.3–11.7). In the first 12 months of life, all infants grew and developed normally compared to WHO standards and a group of infants who were not breastfed. Beyond minor infections common to infancy, no unexpectedly severe or frequent infections arose. Four infants between the ages of 2.1 and 6.2 months who were breastfed after maternal ocrelizumab or rituximab had IgG and CD19 levels within the normal range.

A prospective single-center cohort study of infants, born in 2013 to 2022 were followed up at 6 to 36 months postpartum via telephone interviews. One hundred eighty-three infants who were breastfed during maternal monoclonal antibody therapy for multiple sclerosis or neuromyelitis optica spectrum disorder were matched to infants of disease-modifying therapy-naïve mothers. No differences were found in developmental delay, systemic antibiotic use, severe infections, or hospitalizations. Of the 183 infants, 11 were exposed to rituximab.

A retrospective chart review found one term breastfed infant of a multiple sclerosis patient who received rituximab while breastfeeding (extent not stated). Rituximab was reinitiated 4 weeks postpartum. The infant had blood drawn 12.3 weeks after maternal drug initiation. The infant had a CD19 count within the normal range for age.

Effects on milk supply

Relevant published information was not found as of the revision date.